31 completed, 7 terminated, 4 active not recruiting, 2 not yet recruiting. 26 Phase 1, 25 Phase 2, 4 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Post-transplant Lymphoproliferative Disorder: new trials by email Literature Review of Post-transplant Lymphoproliferative Disorder trials Research Report on Post-transplant Lymphoproliferative Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Utah | 23 | 2026-11-01 | 2026-10-09 |
| 25BT056: Basket Study of Viral Cytotoxic T Lymphocytes Virus-Specific Cytotoxic T Lymphocytes (vCTLs) - EBV Viremia, CMV Viremia | Early Phase 1 | Not yet recruiting | Children's Hospital of Philadelphia | 35 | 2026-11-01 | 2026-10-22 |
| BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine - Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 55 | 2026-06-28 | 2026-07-02 |
| Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation EBV-TCR-T Cell Injection - Epstein-Barr Virus Infection, Post-Transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Recruiting | Daihong Liu | 18 | 2025-06-01 | 2026-01-28 |
| Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) Polatuzumab vedotin, Rituximab, CHP - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 12 | 2023-10-04 | 2026-06-30 |
| Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder Rituximab, Acalabrutinib, CT scans - Post-transplant Lymphoproliferative Disorder | Phase 2 | Terminated | Deepa Jagadeesh | 6 | 2020-09-02 | 2024-04-10 |
| Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial Rituximab - Epstein-Barr Virus Infections, Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Unknown | University Health Network, Toronto | 10 | 2020-07-07 | 2022-08-02 |
| EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients EBV DNA in whole blood and plasma - EBV Infection, EBV Viremia | Completed | University of Aarhus | 509 | 2020-01-03 | 2025-11-20 | |
| Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Everolimus, Tacrolimus, Mycophenolate Mofetil - Pediatric Heart Transplantation, Immunosuppression | Phase 3 | Completed | Boston Children's Hospital | 211 | 2018-01-29 | 2026-07-31 |
| Early Detection of Epstein-Barr Virus Related Disease. Post-transplant Lymphoproliferative Disorder, Mononucleosis | Completed | University of Aarhus | 1527 | 2017-11-01 | 2023-10-31 | |
| Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) Obinutuzumab - Post-transplant Lymphoproliferative Disorder, PTLD | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2017-04-01 | 2017-03-22 | |
| Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas baltaleucel-T - Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse | Phase 2 | Terminated | Cell Medica Ltd | 1 | 2016-11-01 | 2019-03-26 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma | Not applicable | Completed | Mayo Clinic | 29 | 2016-01-19 | 2019-11-15 |
| A Study of the Safety and Efficacy of EBV Specific T-cell Lines Group A, Group B - Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Completed | Dr. Jean-Sebastien Delisle, MD, PhD | 12 | 2015-11-01 | 2025-05-14 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-09-24 | 2026-10-02 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 30 | 2013-10-08 | 2026-06-25 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
Showing 20 of 49. Sign in to see all of them.
Burkitt Lymphoma (35) · Lymphoma, Large B-Cell, Diffuse (34) · Leukemia, Lymphocytic, Chronic, B-Cell (31) · Lymphoma, B-Cell, Marginal Zone (31) · Lymphoma, Follicular (31) · Lymphoma, Mantle-Cell (31) · Waldenstrom Macroglobulinemia (30) · Lymphoma, Large-Cell, Anaplastic (29) · Mycosis Fungoides (29) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (29) · Sezary Syndrome (29) · Lymphoma, Extranodal NK-T-Cell (28) · Immunoblastic Lymphadenopathy (27) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (27) · Hodgkin Disease (26)
DNA Virus Infections (42) · Herpesviridae Infections (42) · Infections (42) · Tumor Virus Infections (42) · Immune System Diseases (41) · Virus Diseases (41) · Hemic and Lymphatic Diseases (40) · Immunoproliferative Disorders (40) · Lymphatic Diseases (40) · Lymphoproliferative Disorders (40) · Neoplasms (39) · Neoplasms by Histologic Type (39) · Lymphoma (36) · Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36)
fludarabine phosphate (11) · Mycophenolic Acid (10) · Peripheral Blood Stem Cell Transplantation (10) · Whole-Body Irradiation (10) · Rituximab (9) · Cyclosporine (8) · Tacrolimus (6) · Cyclophosphamide (5) · Everolimus (3) · Indium (3) · Lenalidomide (3) · Methotrexate (3) · Transplantation (3) · ibritumomab tiuxetan (3) · merphos (3)
Fred Hutchinson Cancer Center (9) · National Cancer Institute (NCI) (9) · City of Hope Medical Center (5) · Mayo Clinic (4) · Case Comprehensive Cancer Center (2) · University of Aarhus (2) · Amir Mortazavi (1) · Boston Children's Hospital (1) · Cell Medica Ltd (1) · Children's Hospital of Philadelphia (1) · Daihong Liu (1) · Deepa Jagadeesh (1) · Dr. Jean-Sebastien Delisle, MD, PhD (1) · Morphotek (1) · Northwestern University (1)
United States (42) · Canada (4) · Italy (4) · Denmark (2) · Germany (2) · China (1) · Norway (1)
David Maloney (4) · Deepa Jagadeesh, MD, MPH (2) · Ryotaro Nakamura (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Amir Mortazavi, MD (1) · Ann Woolfrey (1) · Bente Jespersen, Professor (1) · Brenda Sandmaier (1) · Caitlin Elgarten, MD, MSCE (1) · Christopher S Almond, MD, MPH (1) · Craig Reeder, M.D. (1) · David Scadden (1) · Deepali Kumar (1) · Elizabeth Budde (1)
PMID 32499241, PMID 18698002, PMID 22259028, PMID 24474568, PMID 25686696, PMID 26764356, PMID 26853648, PMID 26943915, PMID 27118452, PMID 28270022, PMID 29292843, PMID 30562587, PMID 31481800, PMID 33315277, PMID 33492438, PMID 34492703, PMID 34515338, PMID 37683299, PMID 40960806, PMID 42720126
P30CA015704 (8), P01CA078902 (3), U01CA097452 (3), P01CA018029 (2), P30CA015083 (2), P30CA016058 (2), U01CA062491 (2), P01CA044991 (1), P30CA014520 (1), P30CA033572 (1), P30CA046592 (1), P30CA072720 (1), P50CA107399 (1), U01CA070019 (1), U01CA076576 (1)